The Things To Think About Before Taking Your Biotech Company Public
The biotech IPOs window is now open, but that doesn’t mean every company can go through it.
The biotech IPOs window is now open, but that doesn’t mean every company can go through it.
Why shouldn’t private investors’ money be literally burned to advance human knowledge?
Explore the mindset, cultural shifts, and training strategies that define the AI‑savvy lawyer, revealing why human judgment, standardized competence, and integrated learning—not technology alone—will shape the future of the profession.
Making room for nonlawyers in law firms.
Read. Your mind will thank you. Maybe not your clients, whose messages you're ignoring, but your mind, yes.
Just wait until the tech bros introduce a smartphone made entirely of lead.
What goes up must come down.
LexisNexis sat down with John Ursin, Managing Partner at Schenck Price, to learn how the firm is using legal AI to strengthen client service and daily legal work.
Most lawyers have saved enough. But saving enough and knowing who you are on the other side of a 35-year career -- those are two completely different problems.
If your choice is a two-dollar Powerball ticket per week or investing those two dollars in the stock market, it’s really no choice at all.
In Trump's America, customized rubber stamps are cheap and plentiful.
And that's just for THIS month.
Legal work isn’t slowing down, and the firms that win won’t be the ones working harder — they’ll be the ones working smarter.
Trump responds to only one thing: the market.
Experts say Hims & Hers’ acquisition of Eucalyptus positions the company for global expansion and revenue diversification amid U.S. GLP-1 regulatory challenges.
Let's cut through the confusion and focus on what actually matters for your planning.
Digital health is entering a more mature phase in 2026 as consolidation accelerates through targeted M&A, driven by the need for scale, artificial intelligence and pressure from payers, investors say.